Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications

被引:31
作者
Velicer, C. M.
Dublin, S.
White, E.
机构
[1] Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98109 USA
[2] VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
关键词
diabetes; insulin; VITAL; cohort; leptin; insulin-like growth factor;
D O I
10.1038/sj.pcan.4500914
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidemiologic evidence suggests diabetic men have a slightly lower prostate cancer risk than nondiabetic men. We examined this association in a prospective cohort study of 35 239 men, 50-76 years old, in Washington State who completed a baseline questionnaire between 2000 and 2002. Incident prostate cancers as of 31 December 2004 were identified through the SEER registry. Diabetic men had a slightly lower risk of prostate cancer than non-diabetic men ( hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.64-1.07). Insulin users overall and insulin users with diabetic complications had decreased risks, compared to non-diabetic men ( HR 0.49, 95% CI 0.26-0.92) and ( HR 0.36, 95% CI 0.15-0.87), respectively. Oral medication use for diabetes was not associated with prostate cancer. Insulin is likely a marker of severity of diabetes. Future studies of this association should consider diabetes type, treatment, severity, complications and biomarkers.
引用
收藏
页码:46 / 51
页数:6
相关论文
共 26 条
[1]  
American Diabetes Association, 2005, ALL DIAB
[2]   Changes in free insulin-like growth factor-1 and leptin concentrations during acute metabolic decompensation in insulin withdrawn patients with type 1 diabetes [J].
Attia, N ;
Caprio, S ;
Jones, TW ;
Heptulla, R ;
Holcombe, J ;
Silver, D ;
Sherwin, RS ;
Tamborlane, WV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (07) :2324-2328
[3]   Diabetes mellitus and risk of prostate cancer: a meta-analysis [J].
Bonovas, S ;
Filioussi, K ;
Tsantes, A .
DIABETOLOGIA, 2004, 47 (06) :1071-1078
[4]   History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE™ (United States) [J].
Chan, JM ;
Latini, DM ;
Cowan, J ;
DuChane, J ;
Carroll, PR .
CANCER CAUSES & CONTROL, 2005, 16 (07) :789-797
[5]   Role of growth factors in the development of diabetic complications [J].
Chiarelli, F ;
Santilli, F ;
Mohn, A .
HORMONE RESEARCH, 2000, 53 (02) :53-67
[6]   Diabetes mellitus and prostate cancer risk among older men: population-based case - control study [J].
Coker, AL ;
Sanderson, M ;
Zheng, W ;
Fadden, MK .
BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2171-2175
[7]   Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass [J].
Fischer, S ;
Hanefeld, M ;
Haffner, SM ;
Fusch, C ;
Schwanebeck, U ;
Köhler, C ;
Fücker, K ;
Julius, U .
ACTA DIABETOLOGICA, 2002, 39 (03) :105-110
[8]  
Giovannucci E, 2003, HORM METAB RES, V35, P694, DOI 10.1055/s-2004-814147
[9]   Diabetes mellitus and risk of prostate cancer (United States) [J].
Giovannucci, E ;
Rimm, EB ;
Stampfer, MJ ;
Colditz, GA ;
Willett, WC .
CANCER CAUSES & CONTROL, 1998, 9 (01) :3-9
[10]   Prostate cancer risk among men with diabetes mellitus (Spain) [J].
González-Pérez, A ;
García Rodríguez, LA .
CANCER CAUSES & CONTROL, 2005, 16 (09) :1055-1058